NEW YORK, Dec. 19-Perlegen Sciences will identify pharmacogenomic markers for Bristol-Myers Squibb, the company said today.
In the partnership, the companies will use Perlegen's chip-based resequencing technology to scan the genomes of hundreds of participants in clinical trials for markers associated with drug response.
Perlegen will apply its collection of more than 1.5 million SNPs to the data in order to identify new markers.
Through the deal, Perlegen will get research funding, milestone payments, royalties, and rights to certain diagnostics.
Financial details of the partnership were not disclosed.
Perlegen is an Affymetrix spinoff based in Mountain View, Calif.